Lehrer Samuel B
Department of Medicine, Section of Clinical Immunology, Allergy and Rheumatology, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA.
Ann Allergy Asthma Immunol. 2004 Nov;93(5 Suppl 3):S19-25. doi: 10.1016/s1081-1206(10)61728-0.
To review allergen risk evaluation for genetically modified foods and our ability to predict protein allergenicity, methods that are being used to develop foods with reduced allergenic activity, and clinical aspects relative to assessing potentially allergic patients.
Information was identified using the MEDLINE database for governmental, international, and industry organizations that have considered possible unintended health effects such as food allergy and how they can be avoided.
The author's knowledge of the field was used to select articles for inclusion in this review.
Organizations have created a decision process that has generally been successful in avoiding development of products that cause allergic reactions. Since some proteins expressed do not have any history of human exposure, risk evaluation may be more of a challenge for them. Biotechnology has also been used to try to develop foods with reduced allergenicity, and in future years such products should yield safer foods.
Allergy risk evaluation for known allergens and genetically modified foods appears to be reasonable and provides assurance of food safety. Allergenicity evaluation of novel proteins is a more complicated process that needs to be and will be improved as our knowledge of food allergens increases. Biotechnology can be used to produce safer and healthier foods; for example, allergenicity of some foods may be reduced through biotechnology. The role of the health care professional in assessing allergic reactions to genetically modified foods is essential and should play a greater role in the interaction of consumers, industry, and regulators.
回顾转基因食品的过敏原风险评估以及我们预测蛋白质致敏性的能力、用于开发低致敏活性食品的方法,以及与评估潜在过敏患者相关的临床方面。
利用MEDLINE数据库识别来自政府、国际和行业组织的信息,这些组织考虑了诸如食物过敏等可能的非预期健康影响以及如何避免这些影响。
作者利用该领域的知识来选择纳入本综述的文章。
各组织已创建了一个决策流程,该流程在避免开发引起过敏反应的产品方面总体上是成功的。由于一些表达的蛋白质没有任何人类接触史,对它们进行风险评估可能更具挑战性。生物技术也已被用于尝试开发低致敏性食品,未来这些产品应能生产出更安全的食品。
对已知过敏原和转基因食品的过敏风险评估似乎是合理的,并能确保食品安全。对新型蛋白质的致敏性评估是一个更复杂的过程,随着我们对食物过敏原的了解增加,这个过程需要并将会得到改进。生物技术可用于生产更安全、更健康的食品;例如,某些食品的致敏性可通过生物技术降低。医疗保健专业人员在评估对转基因食品的过敏反应方面的作用至关重要,并且应该在消费者、行业和监管机构的互动中发挥更大作用。